Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701612 | 0.80 | — | — | |
| SCHEMBL6456147 | 0.77 | CYP2C9 (0.41) | CYP2C9EPHX2EPHX1 | |
| SCHEMBL22073526 | 0.77 | CYP2C9 (0.35) | CYP2C9EPHX2 | |
| SCHEMBL3282039 | 0.77 | CYP2C9 (0.35) | CYP2C9EPHX2 | |
| SCHEMBL18638965 | 0.75 | CYP2C9 (0.39) | CYP2C9EPHX2 | |
| SCHEMBL24433541 | 0.73 | EPHX2 (0.35) | CYP2C9EPHX2EPHX1 | |
| SCHEMBL13085357 | 0.73 | — | — | |
| SCHEMBL12193712 | 0.69 | CYP2C9 (0.35) | CYP2C9EPHX2 | |
| SCHEMBL4412291 | 0.69 | CYP2C9 (0.45) | CYP2C9EPHX2 | |
| SCHEMBL6346244 | 0.66 | CYP2C9 (0.36) | CYP2C9EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-01 | — | — | US | disclosed |
| EP-1554039-B1 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINO)METALLOCENE LIGAND | LUCITE INT UK LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-1534427-B1 | AN ADAMANTYL CATALYST SYSTEM | LUCITE INT UK LTD (GB) | 2009-10-21 | — | — | EP | disclosed |
| US-7485739-B2 | Catalyst system | LUCITE INTERNATIONAL UK LTD. (GB) | 2009-02-03 | — | — | US | disclosed |
| US-7371705-B2 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| US-20060252935-A1 | Catalyst system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-11-09 | — | — | US | disclosed |
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | LUCITE INTERNATIONAL UK LIMITED (GB) | 2006-05-18 | — | — | US | disclosed |
| EP-1554039-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL)FERROCENE LIGAND | Lucite International UK Limited (GB) | 2005-07-20 | — | — | EP | disclosed |
| EP-1534427-A1 | AN ADAMANTYL CATALYTIC SYSTEM | Lucite International UK Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004024322-A2 | A CATALYST SYSTEM COMPRISING A 1,2-BIS-(PHOSPHINOALKYL) FERROCENE LIGAND | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004014552-A1 | A PHOSPHA-ADAMANTANE (S) CATALYTIC SYSTEM | LUCITE INTERNATIONAL UK LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106259-A1 | Phospha-adamantane(s) catalytic system | ADORA2A, ADORA3, ADGRE5 | CYP2C9 1206/4885EPHX2 1360/4885EPHX1 1559/4885 |
| US-20060252935-A1 | Catalyst system | ELOB, SOD1, ESR1 | CYP2C9 436/4885EPHX2 255/4885EPHX1 291/4885 |
| US-20230167145-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | CYP2C9 655/4885EPHX2 2258/4885EPHX1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.